| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 18/02/2025 | 12:07 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section 12(g)] | NASDAQ:RVNC | Revance Therapeutics Inc |
| 13/02/2025 | 11:45 | PR Newswire (US) | Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC | NASDAQ:RVNC | Revance Therapeutics Inc |
| 12/02/2025 | 14:16 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:RVNC | Revance Therapeutics Inc |
| 12/02/2025 | 13:50 | Edgar (US Regulatory) | Form POSASR - Post-effective Amendment to an automatic shelf registration statement | NASDAQ:RVNC | Revance Therapeutics Inc |
| 10/02/2025 | 11:45 | PR Newswire (US) | The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc.(RVNC) Shareholders | NASDAQ:RVNC | Revance Therapeutics Inc |
| 07/02/2025 | 21:46 | Business Wire | Crown Laboratories Completes Acquisition of Revance Therapeutics | NASDAQ:RVNC | Revance Therapeutics Inc |
| 07/02/2025 | 02:06 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:RVNC | Revance Therapeutics Inc |
| 06/02/2025 | 14:59 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:RVNC | Revance Therapeutics Inc |
| 06/02/2025 | 14:39 | PR Newswire (US) | Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics | NASDAQ:RVNC | Revance Therapeutics Inc |
| 06/02/2025 | 11:45 | PR Newswire (US) | The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline | NASDAQ:RVNC | Revance Therapeutics Inc |
| 05/02/2025 | 14:41 | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:RVNC | Revance Therapeutics Inc |
| 05/02/2025 | 14:14 | Edgar (US Regulatory) | Form SC TO-T/A - Tender offer statement by Third Party: [Amend] | NASDAQ:RVNC | Revance Therapeutics Inc |
| 05/02/2025 | 14:00 | PR Newswire (US) | Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer | NASDAQ:RVNC | Revance Therapeutics Inc |
| 03/02/2025 | 11:45 | PR Newswire (US) | Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class Action - RVNC | NASDAQ:RVNC | Revance Therapeutics Inc |
| 31/01/2025 | 13:30 | PR Newswire (US) | Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline | NASDAQ:RVNC | Revance Therapeutics Inc |
| 30/01/2025 | 15:01 | Edgar (US Regulatory) | Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] | NASDAQ:RVNC | Revance Therapeutics Inc |
| 30/01/2025 | 11:45 | PR Newswire (US) | The Gross Law Firm Reminds Revance Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC | NASDAQ:RVNC | Revance Therapeutics Inc |
| 27/01/2025 | 11:45 | PR Newswire (US) | Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact The Gross Law Firm to Learn More | NASDAQ:RVNC | Revance Therapeutics Inc |
| 23/01/2025 | 11:45 | PR Newswire (US) | Shareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC | NASDAQ:RVNC | Revance Therapeutics Inc |
| 21/01/2025 | 14:00 | PR Newswire (US) | Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer | NASDAQ:RVNC | Revance Therapeutics Inc |
| 16/01/2025 | 11:45 | PR Newswire (US) | Revance Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC | NASDAQ:RVNC | Revance Therapeutics Inc |
| 13/01/2025 | 14:30 | PR Newswire (US) | Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc. | NASDAQ:RVNC | Revance Therapeutics Inc |
| 10/01/2025 | 22:52 | Edgar (US Regulatory) | Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors | NASDAQ:RVNC | Revance Therapeutics Inc |
| 09/01/2025 | 11:45 | PR Newswire (US) | The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC | NASDAQ:RVNC | Revance Therapeutics Inc |
| 06/01/2025 | 15:00 | PR Newswire (US) | Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash | NASDAQ:RVNC | Revance Therapeutics Inc |
| 12/12/2024 | 14:01 | Edgar (US Regulatory) | Form SC 14D9 - Solicitation, recommendation statements | NASDAQ:RVNC | Revance Therapeutics Inc |
| 12/12/2024 | 14:00 | PR Newswire (US) | Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share | NASDAQ:RVNC | Revance Therapeutics Inc |
| 12/12/2024 | 13:15 | Edgar (US Regulatory) | Form SC TO-T - Tender offer statement by Third Party | NASDAQ:RVNC | Revance Therapeutics Inc |
| 09/12/2024 | 23:16 | Edgar (US Regulatory) | Form SC TO-C - Written communication relating to an issuer or third party | NASDAQ:RVNC | Revance Therapeutics Inc |
| 09/12/2024 | 15:24 | Edgar (US Regulatory) | Form SC14D9C - Written communication relating to third party tender offer | NASDAQ:RVNC | Revance Therapeutics Inc |
